ArticlePharmacological reports : PR2026
New molecules candidates with a semicarbazide scaffold - anticancer potential in view of research on their physicochemical properties, antioxidant activity, and preliminary biological activity.
Article in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDeveloping semicarbazide-based compounds as potential therapeutic agents is a promising direction in medicinal chemistry, particularly in the context of anticancer drug design. This study reports the synthesis and comprehensive physicochemical characterisation of a series of novel semicarbazide derivatives (AW8, AW12, AW19, AW23, AW33, AW38).
methodsMolecular structures and tautomeric forms in the crystalline state were elucidated using single-crystal X-ray diffraction and supported by detailed Fourier Transform Infrared Spectroscopy (FT-IR) analysis. Incorporation into 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)-based model lipid membranes was evaluated using attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) and Langmuir monolayer techniques. Theoretical absorption, distribution, metabolism, and excretion (ADME) properties and in silico predictions were generated using SwissADME and ADMETlab 3.0 software platforms. Antioxidant potential was assessed using 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) radical scavenging assays, and cytotoxicity against PANC-1 pancreatic cancer cells was determined using the 3-(4,5-di methyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
resultsThe compounds exhibited distinct hydrogen-bonding patterns, conformational preferences driven by substituent-dependent electronic effects, and characteristic supramolecular interactions governing their crystal packing, as confirmed by Hirshfeld surface analysis. Among the tested derivatives, AW8 and AW12 demonstrated the highest membrane affinity, inducing significant spectral alterations and surface pressure changes, indicative of enhanced membrane perturbation associated with chlorine substitution. Absorption, distribution, metabolism, excretion, and toxicity (ADMET) predictions revealed favourable pharmacokinetic profiles, including the potential for blood–brain barrier penetration in selected derivatives and predicted inhibition of P-glycoprotein, a key mediator of multidrug resistance. The compounds demonstrated moderate radical scavenging activity and dose-dependent cytotoxicity against PANC-1 cells.
conclusionThese findings indicate that the studied semicarbazides exhibit promising membrane-active properties, favourable ADME profiles, and biological activity relevant to anticancer drug development, supporting their further evaluation as potential therapeutic candidates.
Indexed as
Identifiers
41784864What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.